Myricetin exerts selective cytotoxic, pro-apoptotic, and anti-metastatic effects on prostate cancer cells by inhibiting PIM1 and disrupting the PIM1/CXCR4 interactions [11]. The gene discussed is PIM1; the disease is prostate carcinoma.